Ajanta Ebitda from 2010 to 2024

AJANTPHARM   3,027  30.05  1.00%   
Ajanta Pharma's EBITDA is increasing with slightly volatile movements from year to year. EBITDA is estimated to finish at about 13.2 B this year. For the period between 2010 and 2024, Ajanta Pharma, EBITDA quarterly trend regression had mean deviation of  3,010,679,876 and range of 12.9 B. View All Fundamentals
 
EBITDA  
First Reported
2014-06-30
Previous Quarter
3.3 B
Current Value
3.3 B
Quarterly Volatility
662.3 M
 
Yuan Drop
 
Covid
Check Ajanta Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ajanta Pharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 B, Interest Expense of 83.5 M or Selling And Marketing Expenses of 42.7 M, as well as many indicators such as . Ajanta financial statements analysis is a perfect complement when working with Ajanta Pharma Valuation or Volatility modules.
  
This module can also supplement various Ajanta Pharma Technical models . Check out the analysis of Ajanta Pharma Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Ajanta Stock

Ajanta Pharma financial ratios help investors to determine whether Ajanta Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Ajanta with respect to the benefits of owning Ajanta Pharma security.